Financials Morphic Holding, Inc.

Equities

MORF

US61775R1059

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:35:59 2024-05-30 am EDT 5-day change 1st Jan Change
30.85 USD +2.49% Intraday chart for Morphic Holding, Inc. +11.06% +6.75%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 523.1 1,044 1,751 1,031 1,437 1,508 - -
Enterprise Value (EV) 1 523.1 1,044 1,751 683 732.2 954.7 980.6 990.1
P/E ratio -6.38 x -22.8 x -17.7 x -17.3 x -8.04 x -7.53 x -6.98 x -6.6 x
Yield - - - - - - - -
Capitalization / Revenue 30.8 x 23.2 x 88.5 x 14.6 x 2,757 x 7,539 x 2,010 x 1,759 x
EV / Revenue 30.8 x 23.2 x 88.5 x 9.65 x 1,405 x 4,774 x 1,307 x 1,155 x
EV / EBITDA - - - - -4.12 x -4.17 x -3.6 x -3.15 x
EV / FCF - -22.4 x - -6.74 x -6.45 x -5.52 x -5.13 x -4.88 x
FCF Yield - -4.46% - -14.8% -15.5% -18.1% -19.5% -20.5%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 30,484 31,125 36,962 38,553 49,743 50,094 - -
Reference price 2 17.16 33.55 47.38 26.75 28.88 30.10 30.10 30.10
Announcement Date 2/27/20 3/1/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 16.98 44.94 19.79 70.81 0.521 0.2 0.75 0.8571
EBITDA 1 - - - - -177.6 -229.2 -272.6 -314.3
EBIT 1 -46.99 -47.18 -95.81 -63.4 -178.7 -227.6 -250.1 -273.3
Operating Margin -276.77% -104.97% -484.02% -89.53% -34,296.74% -113,807.29% -33,352.96% -31,884.57%
Earnings before Tax (EBT) 1 -42.42 -45.57 -95.54 -58.97 -151.7 -202.7 -230.6 -249.4
Net income 1 -43.33 -45 -95.54 -59.04 -152.1 -199 -228.8 -250.1
Net margin -255.22% -100.12% -482.68% -83.38% -29,192.9% -99,514.56% -30,505.09% -29,175.16%
EPS 2 -2.690 -1.470 -2.670 -1.550 -3.590 -3.995 -4.315 -4.564
Free Cash Flow 1 - -46.53 - -101.3 -113.6 -173 -191 -203
FCF margin - -103.54% - -143.12% -21,795.2% -86,500% -25,466.67% -23,683.41%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/27/20 3/1/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 9.556 2.382 60.24 2.055 6.135 0.521 - - - - - 0.0556 0.1667
EBITDA 1 - - - - - - - - -49.15 -53.32 -55.43 -58.94 -62.68
EBIT 1 -21.55 -31.67 26.35 -31.49 -26.58 -39.2 -45.3 -44.75 -49.43 -53.6 -55.51 -58.31 -60.29
Operating Margin -225.47% -1,329.64% 43.74% -1,532.51% -433.27% -7,524.95% - - - - - -104,946.83% -36,170.43%
Earnings before Tax (EBT) 1 -21.4 -31.48 26.84 -29.99 -24.34 -36.1 -38.88 -36.13 -40.61 -45.21 -50.92 -53.1 -56.52
Net income 1 -21.4 -31.48 26.84 -30.02 -24.38 -36.14 -39.01 -36.21 -40.74 -45.29 -49.74 -51.59 -54.42
Net margin -223.96% -1,321.75% 44.56% -1,460.88% -397.34% -6,935.7% - - - - - -92,847.75% -32,653.4%
EPS 2 -0.5800 -0.8500 0.6800 -0.7800 -0.6400 -0.9000 -0.9200 -0.7300 -0.9400 -0.9100 -0.9752 -1.002 -1.059
Dividend per Share - - - - - - - - - - - - -
Announcement Date 2/24/22 5/4/22 8/3/22 11/2/22 2/23/23 4/25/23 8/3/23 11/3/23 2/22/24 4/25/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - 348 704 553 527 518
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -46.5 - -101 -114 -173 -191 -203
ROE (net income / shareholders' equity) - - - - -29.1% -31.9% -54.7% -122%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - 0.54 1.02 0.37 1.24 1 1.25 1
Capex / Sales - 1.21% 5.15% 0.52% 238.2% 500% 166.67% 116.67%
Announcement Date 2/27/20 3/1/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
30.1 USD
Average target price
56 USD
Spread / Average Target
+86.05%
Consensus
  1. Stock Market
  2. Equities
  3. MORF Stock
  4. Financials Morphic Holding, Inc.